ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

POLB Poolbeg Pharma Plc

7.75
0.15 (1.97%)
22 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Poolbeg Pharma Plc LSE:POLB London Ordinary Share GB00BKPG7Z60 ORD 0.02P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.15 1.97% 7.75 7.70 7.80 7.75 7.65 7.70 1,248,169 14:44:24
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 0 -3.93M -0.0079 -9.81 38M
Poolbeg Pharma Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker POLB. The last closing price for Poolbeg Pharma was 7.60p. Over the last year, Poolbeg Pharma shares have traded in a share price range of 7.15p to 15.70p.

Poolbeg Pharma currently has 500,000,000 shares in issue. The market capitalisation of Poolbeg Pharma is £38 million. Poolbeg Pharma has a price to earnings ratio (PE ratio) of -9.81.

Poolbeg Pharma Share Discussion Threads

Showing 3076 to 3099 of 3750 messages
Chat Pages: Latest  126  125  124  123  122  121  120  119  118  117  116  115  Older
DateSubjectAuthorDiscuss
18/4/2024
09:25
AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders-DIVIDEND +5% -PORTFOLIO BROADENED THROUGH ACQUISITION
blackhorse23
15/4/2024
11:49
It is one of their top priorities for this year
inaminute
15/4/2024
09:37
Great this for #POLB Very positive to see the approval of multiple CAR T cell therapies for earlier treatment of multiple myelomaAs an oral preventative therapy for CRS #POLB 001 has the potential to enable broader, safer delivery of cancer immunotherapies to cancer patientshttps://x.com/PoolbegPharma/status/1779751510999752894
burtond1
12/4/2024
13:45
How do u come to that conclusion?
No point in going to the Nasdaq unless you're very very well capitalised.
I'd say a Phase 2 Clinical trial will be necessary expecially since cytokine storm can effect multiple organs

chica1
12/4/2024
13:00
This will be on Nasdaq by year end
inaminute
12/4/2024
10:26
Has CF new venture been ipo’d
anderson3
12/4/2024
09:29
Thanks an interesting read, especially as many quite some way from commercialisation on entry.
peterrr3
11/4/2024
09:15
Was reading this last night
Lots of deals in the Bio--Pharma sectors.
There's a decent amount of reverse mergers onto the Nasdaq with private placements.
Interesting!

www.biospace.com/article/biospace-mergers-and-acquisitions-tracker/

chica1
10/4/2024
18:09
I am optimistic for at least a pump as the grant strike price needs to hold a 70% increase for a couple of weeks or the team won't be happy. I also don't see why they need execs like a full time in house corporate lawyer no matter how good, especially when the IP work is outsourced anyway.I was hoping for the application for an orphan to show fast track and less onerous trial requirements from the Fda along with longer protection but I don't see anything new on Wipo which could flag this.
peterrr3
10/4/2024
10:29
Nope wasn't referring to CF.
POLB001 came out of the Hvivo incubator so that was well before they were acquired.
And the 2 heavy hitters at Amryt that got the original Lojuxta Aergerion deal done were Joe Wiley and Rory Nealon.Im sure the new Ex Amryt hires are all good people but the jury is still out on the strategy.
Making a 360 degree turn from a candidate for severe flu into Oncology is a big move.
Then again lots of drugs have been recalibrated to treat different conditions.2 off the top of my head Botox and Viagra.

chica1
10/4/2024
10:05
I assume you are referring to CF. Without him, you would have no Company. His ability to persuade top class people to to join and manage the company is exemplary.
klosters65
10/4/2024
09:31
Maybe need to spend some time to see if they can find the Finals.


As soon as 'Mouth of Ireland' turns up you can expect chaos.

eeza
10/4/2024
08:31
Cash on hand will be interesting here.
There's alot more pigs at the trough to feed with the new hires.
At this stage I would have thought the hiring of more scientists (who are generally cheap and frugal)would be more beneficial to Poolbeg than an expensive sales and marketing team.
They'll definitely be needing big Pharma help by year end.

chica1
10/4/2024
05:46
A senior moment Hotteruk6?

I know them only too well :-)

lfdkmp
09/4/2024
18:44
oops wrong board
hotteruk6
09/4/2024
18:44
I was expecting more volatility in the share price today.....I think a genuine revaluation has taken place and is fully underwritten at current price. It's now about new premises impact, new contracts....and progress towards that magical 100 mill......could be very boring for a few weeks or longer.
hotteruk6
08/4/2024
18:21
Where are these full year results then?
1gw
03/4/2024
15:32
Some decent chunks going thru.
I need more data before I add again.

chica1
02/4/2024
19:40
Nice to see the rise back above 10p this afternoon. Full year results are overdue by last year's precedent, so hopefully not far away now.
1gw
28/3/2024
15:50
"I feel this is company that has all the right ingredients to be extremely successful." - John Hughman

"My instinct would be - there's going to be lots of really good newsflow. You wouldn't get a team that capable going into a smaller business like Poolbeg unless they saw huge opportunity." - Paul Hill

cf456
27/3/2024
09:28
3080 Could well explain his cash raising from hvo. I expect he needs some cash to get his new venture off the ground and for buying more mining assets off the liquidator.
pierre oreilly
26/3/2024
17:01
Cathal's new toy.
eeza
26/3/2024
07:06
The notice of allowance from the US Patent Office for a #POLB 001 patent featured in @SmallCaps_UKThe claims cover the treatment & prevention of cytokine storm after an immune response has been triggered - in any disease indicationhttps://smallcaps.co.uk/poolbeg-pharma-closer-granting-patent-polb-001-treat-multiple-diseases/
burtond1
22/3/2024
09:46
Bit of interest this morning, up we go.
rafboy
Chat Pages: Latest  126  125  124  123  122  121  120  119  118  117  116  115  Older